Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Dakin, P.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(6)
+
-
Availability
Metadata Only
(6)
+
-
Creation Date
2017
(3)
+
-
Faculty
Leiden University Medical Center (LUMC)
(6)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(6)
+
-
Author
Dakin, P.
(6)
+
-
Wagman, R.B.
(6)
+
-
Bone, H.G.
(5)
+
-
Daizadeh, N.S.
(5)
+
-
Papapoulos, S.
(5)
+
-
Wang, A.
(4)
+
-
Adachi, J.D.
(3)
+
-
Bolognese, M.A.
(3)
+
-
Brown, J.P.
(3)
+
-
Hadji, P.
(3)
+
-
Kendler, D.L.
(3)
+
-
Lin, C.J.F.
(3)
+
-
Recknor, C.
(3)
+
-
Brandi, M.L.
(2)
+
-
Chapurlat, R.
(2)
+
-
Cummings, S.R.
(2)
+
-
Czerwinski, E.
(2)
+
-
Fahrleitner-Pammer, A.
(2)
+
-
Ferrari, S.
(2)
+
-
Lippuner, K.
(2)
+
-
Reginster, J.Y.
(2)
+
-
Show more
Language
en
(6)
+
-
Search results
(1 - 6 of 6)
show grid
show list
save search
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
TEN YEARS OF DENOSUMAB (DMAB) TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM EXTENSION TRIAL
Evolution of subject characteristics in FREEDOM and its extension for up to 8 years
Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years